ENGLEWOOD, Colo., Nov. 2, 2017 /PRNewswire/ -- Aytu BioScience,
Inc. (NASDAQ: AYTU), a specialty life sciences company focused on
global commercialization of novel products in the field of urology,
today announced that the Company will present its operational
results for the fiscal first quarter 2018 on Thursday, November 9, 2017, at 4:30 p.m. ET. The Company will review
recent accomplishments and provide an overview of its business and
growth strategy.
Conference Call Information:
Interested participants and investors may access the conference
call by dialing either:
1 (855) 656-0926 (U.S.)
1 (412) 542-4198 (international)
The webcast will be accessible live and archived on Aytu
BioScience's website, within the Investors section under Corporate
Presentations & Media, at aytubio.com, for 90 days.
A replay of the call will be available for seven days. Access
the replay by calling 1 (877) 344-7529 (U.S.) or 1 (412) 317-0088
(international) and using the replay access code 10114103.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty life sciences
company focused on global commercialization of novel products in
the field of urology, with a focus on products addressing vitality,
sexual wellness, and reproductive health. The Company currently
markets two prescription products in the U.S.: Natesto®, the first
and only FDA-approved nasal formulation of testosterone for men
with hypogonadism (low testosterone, or "Low T") and ProstaScint®
(capromab pendetide), the only FDA-approved imaging agent specific
to prostate specific membrane antigen (PSMA) for prostate cancer
detection and staging. Additionally, Aytu is developing MiOXSYS®, a
novel, rapid semen analysis system with the potential to become a
standard of care for the diagnosis and management of male
infertility caused by oxidative stress. MiOXSYS® is
commercialized outside the U.S. where it is a CE Marked, Health
Canada cleared product, and Aytu is planning U.S.-based clinical
trials in pursuit of 510k medical device clearance by the FDA.
Aytu's strategy is to continue building its portfolio of
revenue-generating products, leveraging its focused commercial team
and expertise to build leading brands within growing markets. For
more information visit aytubio.com. Aytu also now owns wholly-owned
subsidiary Aytu Women's Health (formerly Nuelle, Inc.), a personal
health and wellness company focused on women's sexual wellbeing and
intimacy. Aytu Women's Health markets Fiera, a personal care device
for women that is scientifically proven to enhance physical arousal
and sexual desire. Fiera is a consumer device and is not intended
to treat, mitigate, or cure any disease or medical condition. For
more information about the Fiera personal care device visit
fiera.com.
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, or
the Exchange Act. All statements other than statements of
historical facts contained in this presentation, are
forward-looking statements. Forward looking statements are
generally written in the future tense and/or are preceded by words
such as "may," "will," "should," "forecast," "could," "expect,"
"suggest," "believe," "estimate," "continue," "anticipate,"
"intend," "plan," or similar words, or the negatives of such terms
or other variations on such terms or comparable terminology. These
statements are just predictions and are subject to risks and
uncertainties that could cause the actual events or results to
differ materially. These risks and uncertainties include, among
others: the risks related to not being able to present operational
results for the fiscal first quarter 2018 on Thursday, November 9, 2017, at 2:30 p.m. ET, risks relating to gaining market
acceptance of our products, obtaining reimbursement by third-party
payors, the potential future commercialization of our product
candidates, the anticipated start dates, durations and completion
dates, as well as the potential future results, of our ongoing and
future clinical trials, the anticipated designs of our future
clinical trials, anticipated future regulatory submissions and
events, our anticipated future cash position and future events
under our current and potential future collaboration. We also refer
you to the risks described in "Risk Factors" in Part I, Item 1A of
Aytu BioScience, Inc.'s Annual Report on Form 10-K and in the other
reports and documents we file with the Securities and Exchange
Commission from time to time.
Contact for Investors:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/aytu-bioscience-to-report-fiscal-first-quarter-2018-results-and-business-update-300548110.html
SOURCE Aytu BioScience, Inc.